Phase 1 N=16 Shigella WRSS1 Vaccine Trial in Bangladesh
Diarrhea
Primary: Maximum Severity of Reactogenicity by Vaccination — 1; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=109 A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Single Ascending Dose [SAD] Period) — 2; 2; 1; 0 Participants
Phase 1 N=72 Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects
Electrocardiogram Repolarisation Abnormality · Gonococcal Infection
Primary: The One-sided 95% Confidence Interval (CI) for the Largest Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following…
Phase 1 N=55 Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
Schizophrenia
Primary: Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189 in Schizophrenia Participants — 67.0; 60.5; 161; 81.1 nM
Phase 1 N=21 Characterization of Epilepsy Patients BEEP 2b
Epilepsy
Primary: Mean AUC0-last_ss (Test vs. Reference) — 92.884; 62.76666667; 419.97; 260.3 micro/mL/hr
Phase 1 N=34 Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
Prostatic Hyperplasia
Primary: Cmax — 21700; 20520 pg/mL
Phase 1 N=6 Nivolumab With DC Vaccines for Recurrent Brain Tumors
Malignant Glioma · Astrocytoma · Glioblastoma
Primary: The Safety of Administering DC Vaccines With Nivolumab — 0; 0 Percentage of patients
Phase 1 N=14 Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Indolent Plasma Cell Myeloma · Plasma Cell Myeloma · Smoldering Plasma Cell Myeloma
Primary: Number of Participants Experiencing a Dose-limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 1 N=103 STP206 for the Prevention of Necrotizing Enterocolitis (NEC)
Necrotizing Enterocolitis
Primary: Number and Severity of Adverse Events Experienced by Subjects in Low-dose Treatment Groups — 7; 4; 7; 3 Participants
Phase 1 N=89 A Study of LY2228820 in Participants With Advanced Cancer
Advanced Cancer
Primary: Number of Participants With Clinically Significant Effects (Physical Assessments and Safety Lab Tests) — 1; 3; 2; 3 Participants
Phase 1 N=48 A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet
Japanese Healthy Adult Male
Primary: AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Plasma Concentration for TAK-438 Free Base (TAK-438F) — 190.2…
Phase 1 N=63 Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness
Nicotine Addiction · Serious Mental Illness
Primary: Days of App Use — 34.1; 32 days — p==0.754
Phase 1 N=33 Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
HCV Infection
Primary: Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast — 2058.5; 3872.5; 500.1; 601.2 h*ng/mL
Phase 1 N=3 Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Breast Cancer · Ovarian Cancer · Gynecological Cancer
Primary: Maximum Tolerated Dose (MTD) — NA mg/m2 / mg FD
Phase 1 N=11 Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
Hurler Syndrome
Primary: Percentage of Adherence to the Scheduled Weekly Infusion by the Participants — 99 percentage